Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.

[1]  C. McCarty,et al.  Consanguinity and its association with visual impairment in southern India: the Pavagada Pediatric Eye Disease Study 2 , 2018, Journal of Community Genetics.

[2]  S. Packman,et al.  An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease , 2018, Genetics in Medicine.

[3]  O. Abdul-Rahman,et al.  Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. , 2017, JCI insight.

[4]  H. Lv,et al.  Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation , 2014, BMC Medical Genetics.

[5]  C. Rehder,et al.  Predicting cross‐reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience , 2012, American journal of medical genetics. Part C, Seminars in medical genetics.

[6]  Yuan-Tsong Chen,et al.  The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease , 2011, Genetics in Medicine.

[7]  J. E. Wraith,et al.  Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience , 2010, Journal of Inherited Metabolic Disease.

[8]  J. Clancy,et al.  Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease , 2009, Pediatric Research.

[9]  S. Marie,et al.  Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations , 2009, Journal of Neurology.

[10]  B. Byrne,et al.  Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease , 2009, Genetics in Medicine.

[11]  D. Halley,et al.  Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating , 2008, Human mutation.

[12]  A. D’Amico,et al.  Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe disease , 2008, Human mutation.

[13]  S. Marie,et al.  Deconstructing Pompe Disease by Analyzing Single Muscle Fibers: “To See a World in a Grain of Sand…” , 2007, Autophagy.

[14]  W. Hwu,et al.  Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease , 2007 .

[15]  B. Bembi,et al.  Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II , 2006, Human mutation.

[16]  G. Herman,et al.  Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[17]  David M. Rapoport,et al.  Pompe disease diagnosis and management guideline , 2006, Genetics in Medicine.

[18]  Wuh-Liang Hwu,et al.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[19]  D. V. Leenen,et al.  Twenty‐two novel mutations in the lysosomal α‐glucosidase gene (GAA) underscore the genotype–phenotype correlation in glycogen storage disease type II , 2004, Human mutation.

[20]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[21]  M. Roig,et al.  Identification of six novel mutations in the acid alpha-glucosidase gene in three Spanish patients with infantile onset glycogen storage disease type II (Pompe disease) , 2002, Neuromuscular Disorders.

[22]  F. Martiniuk,et al.  Identification of two subtypes of infantile acid maltase deficiency. , 2000, The Journal of pediatrics.

[23]  N. Karabul,et al.  Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany. , 2015, JIMD reports.

[24]  H. Mandel,et al.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. , 2010, Molecular genetics and metabolism.

[25]  A. McVie-Wylie,et al.  Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. , 2001, Genetics in medicine : official journal of the American College of Medical Genetics.

[26]  J. Shieh,et al.  Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: Evidence for a founder effect , 1998, Human mutation.